SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (546)4/25/2000 9:38:00 AM
From: GeoDude  Read Replies (1) of 666
 
Coulter Pharmaceutical Reacquires Rights to Bexxar Outside of the U.S. from SmithKline Beecham

Looks to me that SB does not see big potential in this drug. Not the elephant that big pharma needs. Decided to pass it on to a partner with lower overheads (CLTR). Unless SB is wrong, not good news for CLTR. Of course SB could be wrong ... Have they been wrong before?

LIA
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News